AMGN:
Current live price is 336.48, representing a percentage change of +1.85%.
Support and Resistance Levels
Current support levels are 336.48, 336.48, and 336.48, while resistance levels are 336.48, 336.48, and 336.48. The pivot point is also 336.48.
Indicators
RSI is at 57.27, showing an upward trend. ATR is at 0.65199. The Parabolic SAR is at 336.48. The MACD indicates a slight bullish momentum with MACD at 0.49435 and Signal at 0.48179.
Market Sentiment
Price is above the pivot point of 336.48, supporting a bullish trend due to positive indicators.
AMGN Signals & Technical Analysis
Last Updated: <% indicators.interval.updated|date:'MMM d, y h:mm:ss a' %>
Amgen Inc. (NASDAQ: AMGN), founded in 1980, is one of the world’s largest biotechnology companies, dedicated to discovering, developing, manufacturing, and delivering innovative human therapeutics. Based in Thousand Oaks, California, Amgen focuses primarily on the treatment of serious illnesses in areas such as oncology, nephrology, and inflammation. With a commitment to scientific excellence, the company leverages its proprietary research and advanced technologies to create groundbreaking therapies that improve patient outcomes.
Market Position
Amgen holds a prominent position in the global biopharmaceutical industry, being recognized for its robust portfolio of products, including blockbuster medications like Enbrel, Neulasta, and Prolia. The company’s innovative approach, combined with its strong emphasis on research and development, has enabled it to maintain a competitive edge within the biotechnology sector. As of 2023, Amgen continues to progress through a pipeline rich with potential treatments that address unmet medical needs, further solidifying its status as a leader in the industry.
Key Financial Highlights
In its most recent fiscal year, Amgen reported impressive financial performance, with revenues exceeding $26 billion and a net income of $7 billion. The company has consistently demonstrated strong operating cash flow, allowing for strategic investments in research and development along with shareholder returns through dividends and stock buybacks. Furthermore, Amgen’s commitment to operational efficiency has resulted in a favorable gross margin, reinforcing its financial stability in a competitive marketplace.
Industry Highlights
The biotechnology industry is poised for significant growth, driven by advancements in personalized medicine and increasing demand for novel therapies. Amgen is well-positioned to capitalize on this growth, with a strong emphasis on innovation and a robust pipeline of therapies currently in various stages of development. The company’s strategic collaborations and partnerships within the healthcare ecosystem further enhance its ability to deliver cutting-edge solutions to patients worldwide.
<% (signals.list.current.rate).substr(0,7) %>
<% signal.analyst %>
